Corporate Update

Rhea-AI Summary

Vystar Corporation (OTCQB: VYST) announced its upgrade from Pink Sheets to the OTCQB Exchange following Form 15C-211 approval. The company reports 17,400,614 shares outstanding and has successfully eliminated $11 million in debt through removing $5 million in Rotmans lease debt and $6 million in loans.

The company is focusing on three main business areas:

• Vytex - Allergy-free natural rubber latex products including foam, gloves, and condoms
• RXAIR - Air purification systems ranging from $500 personal units to $6,000 industrial units, with over 20,000 residential and 400 hospital units sold
• Fluid Energy Conversion (FEC) - Hughes Reactor technology for various applications including flow meters, water treatment, and combustion enhancement

Vystar's strategy involves growing existing product lines and exploring M&A opportunities, leveraging its $60 million loss carry forward and patent-protected product portfolio.

Positive

• Uplisting from Pink Sheets to OTCQB Exchange, increasing stock visibility and potential liquidity
• Removal of $11M in debt obligations ($5M Rotmans lease + $6M loans)
• Strong IP protection across product lines (Vytex, RXAIR, FEC) with FDA approvals
• Substantial inventory of FDA-approved products warehoused in US
• Successful track record of 20,000+ residential and 400 hospital RXAIR units sold
• Medical device exemption from recent tariffs
• $60M loss carry forward potentially attractive for M&A transactions

Negative

• Closure of Rotmans furniture division, indicating business segment discontinuation
• Heavy reliance on potential M&A transactions for future growth
• Limited current revenue streams mentioned
• Small market cap with only 17.4M shares outstanding

Boston, MA, April 30, 2025 (GLOBE NEWSWIRE) -- Vystar^® Corporation (OTCQB: VYST) Vystar received notice of final approval of its Form 15C-211 application. In addition, today the Company moved from the Pink Sheets to the OTCQB Exchange. The Company currently has 17,400,614 shares outstanding. This move marks an important milestone for Vystar as it allows for increased visibility and liquidity in the Company’s stock.

Formal notice from the OTCQB will be circulated on Monday. Vystar wants to thank the outstanding staff at the OTC Markets Group for their time and diligence working with Vystar in this process. The 15C-211 filing is a complex process that requires a multitude of reviews. The OTC Markets Group staff members worked meticulously with Vystar to ensure documentation was in order for final submission.

Vystar’s Moves For Shareholder Value

Vystar continues to move forward for the benefit of our shareholders. Vystar is working with its talented board members, larger shareholders and professions on a path of renewed intensity for success that it continues to maintain. This success and Vystar’s accomplishments are due to their tireless work.

Vystar’s promise and continued intent to streamline the business of the Company resulted in the removal of $5 million in Rotmans lease debt and an additional $6 million in loans from the Company’s obligations. This comports with Vystar’s closing of Rotmans, the Company’s furniture division. Vystar is redirecting its resources to its specialty manufacturing.

Vystar’s Concentrated Business

The three main areas of focus now are on Vytex, RXAIR, and Fluid Energy Conversion (FEC). Vystar is confident it can succeed in spaces where it can make outstanding products that are protected by patents and copyrights. This precludes potential competitors from seeking to duplicate Vystar’s products.

Vytex Allergy Free Natural Rubber Latex – The Company owns the formulations and intellectual property that creates what Vystar believes to be the highest quality products as against any competitor’s products.

By way of example, Vystar can manufacture allergy and ammonia free natural latex products ranging from: (i) foam utilized in pillows, mattresses and toppers; (ii) gloves; (iii) condoms; and (iv) and other latex products. The Company believes its FDA approved products are unrivaled in the industry and maintains a substantial inventory warehoused in the United States.

RXAIR Residential and Medical Air Purification – Vystar has built a line of products for the home and medical facilities. The product lines range from a personal $500 unit to an industrial $6,000 unit for hospitals or similarly situated medical services. Vystar owns the patents and has achieved FDA approval, as well as EPA, CARB and other air purification certifications. Vystar has sold more than 20,000 residential and 400 hospital units RXAIR Video's. In addition, Vystar has invested in manufacturing and high-speed tooling for the units. These units are built to eliminate germs, viruses and bacteria. Vystar maintains a stockpile of more than a thousand units and replacement cartridges. Also important, Vystar is under a medical device exemption from the recent tariffs. RXAIR AIR PURIFIER ONLINE STORE.

FEC - The Hughes Reactor changes flow of liquid or gas into sound waves. The sound can be brought to powerful levels using a mechanism that has no moving parts. This allows the reactor the ability to harness the energy into various uses. The uses for this patented technology include: Flow Meter, hard water abatement, air purification, multiple dialysis applications and combustion enhancements for natural gas, biofuels, gasoline. This energy is powerful, clean, and controllable. It can be used to measure flow, to push forward chemical reactions such as combustion, or to mix chemicals together thoroughly and instantly. All of this technology is protected by Vystar’s intellectual property.

Moving Forward

The Company’s strategy is twofold. First, to ensure continued growth of its product lines and secondly, exploring M&A transactions that seek to match synergies with a counter-entity(ies) that would allow Vystar to expand its market share and gain further operational efficiency while greatly enhancing the share price.

With Vystar’s unique product lines and a $60 million loss carry forward, Vystar projects to be a tempting transaction for a “like for like” partner. Depending upon the partner, there is always the potential that a M&A transaction could include a spin-out of certain assets and result in more than one final public entity. Second, the Company continues to work to increase its current sales lines as well as utilize its protected products within new sectors of the economy.

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

Contact Vystar:
Distributor Opportunities: info@rxair.com 
Media, Investors or To Partner with Vystar, Company Phone Number: (508) 791-9114

FAQ

What does Vystar's (VYST) move to OTCQB from Pink Sheets mean for investors?

Vystar's move to OTCQB from Pink Sheets, announced April 30, 2025, provides increased visibility and liquidity for the stock. The company received final approval of its Form 15C-211 application, marking an important milestone with 17,400,614 shares outstanding.

How much debt has Vystar (VYST) eliminated in its recent restructuring?

Vystar has eliminated $11 million in total debt, including $5 million in Rotmans lease debt and $6 million in loans, following the closure of its furniture division to focus on specialty manufacturing.

What are the three main business segments of Vystar (VYST) in 2025?

Vystar's three main business segments are: Vytex (allergy-free natural rubber latex products), RXAIR (residential and medical air purification systems), and FEC (Fluid Energy Conversion technology for various industrial applications).

How many RXAIR units has Vystar (VYST) sold to date?

Vystar has sold over 20,000 residential RXAIR units and 400 hospital units. The company maintains an inventory of more than 1,000 units and replacement cartridges, with prices ranging from $500 for personal units to $6,000 for industrial units.

What are Vystar's (VYST) current M&A strategy and growth plans?

Vystar is pursuing a dual strategy: growing existing product lines and exploring M&A opportunities with synergistic partners. With a $60 million loss carry forward and unique product lines, the company aims to expand market share and enhance operational efficiency.